Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials

Objective To assess the effect of fezolinetant treatment on health‐related quality of life using pooled data from SKYLIGHT 1 and 2 studies. Design Prespecified pooled analysis. Setting USA, Canada, Europe; 2019–2021. Population 1022 women aged ≥40 to ≤65 years with moderate‐to‐severe vasomotor sympt...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	BJOG : an international journal of obstetrics and gynaecology 2024-08, Vol.131 (9), p.1296-1305
Hauptverfasser:	Cano, Antonio, Nappi, Rossella E., Santoro, Nanette, Stute, Petra, Blogg, Martin, English, Marci L., Morga, Antonia, Scrine, Ludmila, Siddiqui, Emad, Ottery, Faith D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trials fezolinetant health‐related quality of life Menopause neurokinin 3 receptor antagonist patient‐reported outcomes Placebos Quality of life vasomotor symptoms Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!